Medical News

November 13 2003–Today, new knowledge in pathology drives a development of more targeted drugs. This 500 page report structures and analyzes the new generation of targeted therapeutics for the
treatment of cancer.

In the field of cancer therapeutics, cytotoxic drugs will be replaced with treatments based on a biological approach. Hopefully these new therapies will take over the market not only by increasing the efficacy, but also by significantly decreasing the devastating and troublesome side effects elicted by chemotherapy. Bioseeker along with other analysts believes that this will soon have a substantial impact on the market. Rituxan is one obvious example of this transition.

Novel therapeutic strategies include immunotherapy, vascular targeting, antisens, gene therapy, targeted therapeutics and apototic induction have been studied to reveal mainly industry progress but as well key scientific breakthroughs. Several hundreds of therapeutic candidates are competing in this enviroment and many of them will never succeed, whereas a few will turn out to be the big winners.

This Highlight Report will provide you with an update on the early failure of drugs in anti-angiogenesis such as Avastin, Erbitux, SU5416, Marimastat, Endostatin and Angiostatin. The report will also provide you with an update on the recent advances on vascular targeting, the next approach to inhibit angiogenesis. The progress made in gene therapy where only limited number of companies is in late stage clinical trials is also presented. Updates are also given for the development that occurs in the antisense technology, where the drug Affinitek recently failed to prolong the life of lung cancer patients. However, several big drug companies have partnered with antisense drug developers in the hope that the technology might prove succesful. Furthermore, the report gives an overview on the most recent advancements made by pharmaceutical companies in their choice of therapeutic targets, to induce the apoptotic pathways. A field where a number of antisense related companies play an important role, most notorius the antisense agent Genasense, which targets Bcl-2.

For a complete index of this report click on
http://www.researchandmarkets.com/reports/40093

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

November 13 2003–Today, new knowledge in pathology drives a development of more targeted drugs. This 500 page report structures and analyzes the new generation of targeted therapeutics for the
treatment of cancer.

In the field of cancer therapeutics, cytotoxic drugs will be replaced with treatments based on a biological approach. Hopefully these new therapies will take over the market not only by increasing the efficacy, but also by significantly decreasing the devastating and troublesome side effects elicted by chemotherapy. Bioseeker along with other analysts believes that this will soon have a substantial impact on the market. Rituxan is one obvious example of this transition.

Novel therapeutic strategies include immunotherapy, vascular targeting, antisens, gene therapy, targeted therapeutics and apototic induction have been studied to reveal mainly industry progress but as well key scientific breakthroughs. Several hundreds of therapeutic candidates are competing in this enviroment and many of them will never succeed, whereas a few will turn out to be the big winners.

This Highlight Report will provide you with an update on the early failure of drugs in anti-angiogenesis such as Avastin, Erbitux, SU5416, Marimastat, Endostatin and Angiostatin. The report will also provide you with an update on the recent advances on vascular targeting, the next approach to inhibit angiogenesis. The progress made in gene therapy where only limited number of companies is in late stage clinical trials is also presented. Updates are also given for the development that occurs in the antisense technology, where the drug Affinitek recently failed to prolong the life of lung cancer patients. However, several big drug companies have partnered with antisense drug developers in the hope that the technology might prove succesful. Furthermore, the report gives an overview on the most recent advancements made by pharmaceutical companies in their choice of therapeutic targets, to induce the apoptotic pathways. A field where a number of antisense related companies play an important role, most notorius the antisense agent Genasense, which targets Bcl-2.

For a complete index of this report click on
http://www.researchandmarkets.com/reports/40093

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com